Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Hepatitis C virus infection in children and adolescents
 
  • Details

Hepatitis C virus infection in children and adolescents

Journal
The Lancet Gastroenterology and Hepatology
Journal Volume
4
Journal Issue
6
Pages
477-487
Date Issued
2019
Author(s)
Indolfi G.
Easterbrook P.
Dusheiko G.
El-Sayed M.H.
Jonas M.M.
Thorne C.
Bulterys M.
Siberry G.
Walsh N.
MEI-HWEI CHANG  
Meyers T.
Giaquinto C.
Wirth S.
Chan P.-L.
Penazzato M.
DOI
10.1016/S2468-1253(19)30046-9
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065067351&doi=10.1016%2fS2468-1253%2819%2930046-9&partnerID=40&md5=5b9571773a3b5fd741c0c8646d83a7f2
https://scholars.lib.ntu.edu.tw/handle/123456789/536918
Abstract
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and associated morbidity and mortality worldwide. Short-course, oral, curative, direct-acting antiviral regimens have transformed treatment for HCV infection. Since the 2016 launch of the first global strategy towards elimination of viral hepatitis as a public health threat by 2030, the predominant focus of the global response has been on the treatment of adults, who bear the greatest burden of morbidity and mortality of HCV-related chronic liver disease. Compared with adults, there has been little attention paid to addressing the response to HCV in children and adolescents, in part because of the scarcity of data to inform specific paediatric management practices and policy. In this Series paper, we summarise knowledge on the epidemiology, natural history, and treatment of chronic HCV infection in adolescents and children, and we highlight key differences from infection acquired in adulthood. The estimated global prevalence and burden of HCV infection in children aged 1–19 years is 0·15%, corresponding to 3·5 million people (95% CI 3·1–3·9 million). HCV infection is usually asymptomatic during childhood, and cirrhosis and hepatocellular carcinoma are rare. Sofosbuvir with ledipasvir and sofosbuvir with ribavirin have received regulatory approval and guidelines recommend their use in adolescents aged 12 years and older with HCV infection. In April, 2019, glecaprevir with pibrentasvir also received regulatory approval for adolescents aged 12–17 years. Key actions to address the current policy gaps and achieve treatment scale-up that is comparable to that in adults include: establishment of a campaign on access to testing and treatment that is targeted at children and adolescents; fast-track evaluation of pan-genotypic regimens; and accelerated approval of paediatric formulations. Research gaps that need to be addressed include: age-specific prevalence studies of HCV viraemia in priority countries; further validation of non-invasive tests for staging of liver disease in children; and establishment of paediatric treatment registries and international consortia to promote collaborative research agendas. ? 2019 World Health Organization. Published by Elsevier Ltd. All rights reserved.
SDGs

[SDGs]SDG3

Other Subjects
aspartate aminotransferase; dasabuvir plus ombitasvir plus paritaprevir plus ritonavir; elbasvir plus grazoprevir; glecaprevir plus pibrentasvir; hepatitis C vaccine; ledipasvir plus sofosbuvir; ombitasvir plus paritaprevir plus ritonavir; ribavirin; sofosbuvir; sofosbuvir plus velpatasvir; alanine aminotransferase; antivirus agent; aspartate aminotransferase; hepatitis B surface antigen; antiviral therapy; clinical trial (topic); disease burden; disease exacerbation; episiotomy; hepatitis C; Hepatitis C virus; human; liver cell carcinoma; liver cirrhosis; liver disease; prevalence; priority journal; Review; sexual transmission; transient elastography; treatment duration; viral clearance; viremia; virus hepatitis; virus transmission; adolescent; blood; child; diagnostic imaging; elastography; female; harm reduction; hepatitis B; practice guideline; pregnancy; pregnancy complication; prevention and control; vertical transmission; Adolescent; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Child; Clinical Trials as Topic; Elasticity Imaging Techniques; Female; Harm Reduction; Hepatitis B; Hepatitis B Surface Antigens; Humans; Infectious Disease Transmission, Vertical; Liver Cirrhosis; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious
Publisher
Elsevier Ltd
Type
review

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science